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Abstract
Although non-melanoma skin cancer (NMSC) is the most common
human cancer and its incidence continues to rise worldwide, the mech-
anisms underlying its development remain incompletely understood.
Here, we unveil a cascade of events involving peroxisome proliferator-
activated receptor (PPAR) b/d and the oncogene Src, which promotes
the development of ultraviolet (UV)-induced skin cancer in mice. UV-
induced PPARb/d activity, which directly stimulated Src expression,
increased Src kinase activity and enhanced the EGFR/Erk1/2 signalling
pathway, resulting in increased epithelial-to-mesenchymal transi-
tion (EMT) marker expression. Consistent with these observations,
PPARb/d-null mice developed fewer and smaller skin tumours, and
a PPARb/d antagonist prevented UV-dependent Src stimulation.
Furthermore, the expression of PPARb/d positively correlated with
the expression of SRC and EMT markers in human skin squamous
cell carcinoma (SCC), and critically, linear models applied to several
human epithelial cancers revealed an interaction between PPARb/d
and SRC and TGFb1 transcriptional levels. Taken together, these
observations motivate the future evaluation of PPARb/d modula-
tors to attenuate the development of several epithelial cancers.
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Introduction
The incidence of non-melanoma skin cancer (NMSC) is increasing
at a high rate (3–8% yearly), with over one million estimated new
cases each year in the United States alone (Madan et al, 2010).
Squamous cell carcinoma (SCC) and basal cell carcinoma, which
both derive from keratinocytes, are the most common types of
NMSC. Although mortality due to NMSC is low, its morbidity is high
and is accompanied by heavy personal burden and enormous, rising
costs for society. NMSCs are associated with excessive and/or
chronic exposure to ultraviolet (UV) radiation and mainly occur on
sun-exposed areas. In particular, UVB radiation (290–320 nm, sun-
burn rays) predominantly affects keratinocytes because of its low
skin penetration and is believed to act as a carcinogen (Ehrhart
et al, 2003). Despite the prevalence of NMSCs, the mechanisms
underlying their progression remain poorly defined.
Tumours have often been referred to as ‘wounds that never
heal’. Gene expression profiling, which has revealed that a wound-
response gene expression pattern predicts metastasis, survival likeli-
hood and response to chemotherapy in cancer patients, supports
this concept (Bissell & Radisky, 2001; Chang et al, 2004; Farmer
et al, 2009; Nuyten & van de Vijver, 2006; Schafer & Werner, 2008).
Apoptosis resistance, cell proliferation and migration, matrix remod-
elling, and angiogenesis are processes of life-saving importance after
an injury but are also common features of tumour progression. The
identification of molecular regulators of the mechanisms that acti-
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vate, sustain and eventually shut down these processes may
advance our understanding of tumour development in general and
of NMSC in particular.
Our previous work on skin wound healing in mice demonstrated
the importance of the peroxisome proliferator-activated receptors
(PPARs), members of the nuclear receptor superfamily, in tissue
repair (Michalik et al, 2001). Injury strongly stimulates expression
of PPARa (NR1C1) and PPARb/d (NR1C2) in keratinocytes at the
edges of skin wounds, and individual genetic deletion of these iso-
types delays healing (Michalik et al, 2001). Both PPARa and
PPARb/d affect the early inflammatory reaction, but PPARb/d-null
mice exhibit additional defects in healing resulting from impaired
keratinocyte adhesion and migration, as well as increased apoptosis
at wound edges (Di-Poi et al, 2002; Michalik et al, 2005; Tan et al,
2001; Tan et al, 2007). Thus, during wound healing, inflammation-
induced PPARb/d controls processes that are also involved in carci-
nogenesis. Whether PPARb/d is pro- or anti-carcinogenic remains
controversial, however, because both effects have been observed
(Michalik et al, 2004; Muller-Brusselbach et al, 2007; Peters &
Gonzalez, 2009; Schug et al, 2007; Schug et al, 2008). To address
this question, we investigated PPARb/d function in keratinocyte-
derived UV-induced skin tumours. Here, we unveil a previously
unrecognized control by PPARb/d over a pro-oncogenic pathway,
identifying PPARb/d as a key focus for further epithelial cancer
studies.
Results
UV radiation stimulates PPARb/d expression and activity,
enhancing skin tumour formation and progression in vivo
To test if PPARb/d is implicated in UV-dependent tumour develop-
ment, we first investigated whether its expression responds to UV
radiation. SKH-1 hairless mice were exposed to chronic low-dose
UV radiation for up to 31 weeks to mimic repeated exposure to sun-
light. Interestingly, Pparb/d expression increased in dorsal skin
upon chronic UV exposure, Ppara expression was reduced
and Pparc expression was unchanged (Fig 1A, left) (supplementary
Fig S1). Additionally, the expression of Tgfb1 and Plin2, two
well-known PPARb/d target genes, was stimulated in wild-type but
not in Pparb/d/ mice, indicating activation of the receptor
(Fig 1A). Importantly, when wild-type and Pparb/d/SKH-1
hairless mice were subjected to chronic UV radiation, tumour inci-
dence and multiplicity were much higher in wild-type mice com-
pared toPparb/d/ mice during the course of chronic UV exposure
(Fig 1B). Wild-type mice fulfilled the criteria for withdrawal from
the experiment (tumour larger than 9 mm in diameter) earlier
than Pparb/d/ mice (Fig 1C, D). Eventually, a 100% tumour inci-
dence was reached in both genotypes after 22 weeks of UV expo-
sure, which might have resulted from gene mutations arising from
long-term UV exposure and associated modifications in gene expres-
sion in the Pparb/d/ mice, which override the inhibitory effect
of Pparb/d deficiency on tumourigenesis. Nevertheless, the growth
rate of the tumours and their final size were higher in wild-type
mice (Fig 1E).
To gain additional support for a Pparb/d-specific response to
UV exposure, the SKH-1 mice were exposed to a single acute UV
dose and sacrificed 24 h later. The UV treatment caused enhanced
erythema in wild-type mice, characterized by an increased expres-
sion of inflammatory markers (supplementary Fig S2A). As with
chronic irradiation, PPARb/d expression and activity were
enhanced in the skin of wild-type animals upon acute UV expo-
sure, especially in the epithelial compartment where carcinomas
arise, as documented by the stimulation of two known target
genes, Tgfb1 and Plin2 (Fig 1F) (supplementary Fig S2B). These
observations suggest a major function for PPARb/d in the initia-
tion and progression of skin tumours in response to UV
irradiation.
Increased levels of activated PPARb/d enhance Src expression
Our previous gene expression analyses indicated a higher expres-
sion of the tyrosine kinase Src, a well-characterized proto-oncogene
and enhancer of skin carcinoma (Guasch et al, 2007; Joseloff et al,
2002; Matsumoto et al, 2003; Matsumoto et al, 2004; Serrels et al,
2009; Yagi et al, 2007), in wild-type versus Pparb/d/ primary
keratinocytes (supplementary Fig S3A) (Montagner et al, 2011). In
Figure 1. PPARb/d is over-expressed and activated upon UV radiation and enhances skin tumour formation and growth.
A Quantification of Pparb/d (left), Tgfb1 (middle) and Plin2 (right) expression by RT-PCR in non-tumoural dorsal skin of chronically irradiated (Ch-UV, +) or non-
irradiated () Pparb/d+/+ and Pparb/d/ mice. Values from non-irradiated dorsal skin of Pparb/d+/+ mice (left) or from irradiated dorsal skin of Pparb/d/ mice
(right) were set to 1. Means  SEM of 13 Pparb/d+/+ and 9 Pparb/d/ mice are presented. p-values are *p = 0.035 for Pparb/d (left); *p = 0.025 and **p = 0.008
for Tgfb1(middle); **p = 0.078 and ***p = 0.0003 for Plin2 (right) calculated by two-tailed Student’s t-test.
B,C Percentage of Pparb/d+/+ and Pparb/d/ mice bearing tumours (B) and average number of tumours per mouse (C) measured at the indicated time points of UV
exposure. For (C), p-values are *p = 0.025, **p = 0.008, ***p = 0.0001 calculated by two-tailed Student’s t-test. Data for 13 Pparb/d+/+ and 9 Pparb/d/ mice are
presented.
D Percentage of Pparb/d+/+ and Pparb/d/ mice involved in the experiment over time. Mice were withdrawn from the experiment based on criteria given in the
Material and Methods section.
E Tumour growth rate (left) and final size (right) from Pparb/d+/+ and Pparb/d/ mice measured before sacrifice. Means  SEM for 13 Pparb/d+/+ and 9 Pparb/d/
 mice are presented. p-values are **p = 0.009 for tumour growth rate (left) and *p = 0.045 for tumour size (right) calculated by two-tailed Student’s t-test.
F Measurement of Pparb/d (left), Tgfb1 (middle) and Plin2 (right) expression by RT-PCR in dermis and epidermis compartments of dorsal skin of Pparb/d+/
+ and Pparb/d/ mice 24 h after acute UV (Ac-UV) irradiation. Values from dermis of non-irradiated dorsal skin of Pparb/d+/+ mice (left) or from dermis of Ac-UV
dorsal skin of Pparb/d/ mice (middle and right) were set to 1. Means  SEM for 12 Pparb/d+/+and 12 Pparb/d/ mice are presented. Values are representative of
three independent experiments; p-values are *p = 0.025, **p = 0.007, ***p = 0.002 for Pparb/d; ***p = 0.0003, *p = 0.049, **p = 0.0093, ***p = 0.0041,
***p = 0.0004 from top to bottom for Tgfb1; ***p = 0.0048, ***p = 0.0013, ***p = 0.0006, ***p = 0.0009, **p = 0.0071, ***p = 0.0035, ***p = 0.0029 from top to
bottom and from left to right for Plin2 calculated by two-tailed Student’s t-test; ns, not significant.
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addition to Src, the Fyn and Yes tyrosine kinases, which also belong
to the Src family kinases, were expressed in skin (Fig 2A) (supple-
mentary Fig S3B). Interestingly, acute UV irradiation caused a
selective PPARb/d-dependent enhancement of Src mRNA and pro-
tein expression in vivo (Fig 2A, B) (supplementary Fig S3B). Simi-
larly, Src mRNA and protein levels were consistently and strikingly
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higher in vivo in chronically irradiated wild-type skin versus Pparb/
d/ skin (Fig 2C, D). This effect was selective since the expression
of Fyn and Yes was not affected after chronic irradiation (supple-
mentary Fig S3C).
The highest PPARb/d-dependent Src expression occurred in the
epidermis, mainly in keratinocytes of the lower layers (Fig 2A, E)
(supplementary Fig S4) where PPARb/d has been localized (Micha-
lik et al, 2001). Consistent with these observations, human immor-
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talized keratinocytes (HaCaT cells) stimulated with the PPARb/d
agonist GW501516 exhibited higher Src mRNA and protein expres-
sion, similar to ANGPTL4, which was used as a positive control of
PPARb/d activity (supplementary Fig S5A, B) (Kersten et al, 2000;
Rieck et al, 2008). Characterization by 5′ RACE and sequencing of
the Src transcript induced in a PPARb/d-dependent manner by
GW501516 in primary keratinocyte culture or by UV in mouse skin
indicated its correspondence with the Src-001 transcript described in
Ensembl (ENSMUST00000029175) (Fig 3A, B). In silico Src analysis
revealed five peroxisome proliferator response elements (PPREs),
which resemble the consensus PPRE motif, in the intragenic Src regu-
latory region (Fig 3A) (supplementary Fig S5C). These elements were
potentially responsive to PPARb/d activation in a reporter assay
(Fig 3C), indicating that Src is likely to be a PPARb/d target gene.
This finding is in agreement with PPARb/d-induced SRC expression
in the absence of de novo protein synthesis (supplementary Fig S5D).
To determine whether these PPREs serve as binding sites for
PPARb/d, chromatin immunoprecipitation (ChIP) PPARb/d experi-
ments followed by re-ChIP p300, a PPARb/d co-activator, were per-
formed using lysates from control (wild-type) and PPARb/d-
knockdown (KD) mouse keratinocytes (MKs, Fig 3D, E). The endog-
enous PPARb/d of KD cells was strongly downregulated by siRNA
(supplementary Fig S5E). PPARb/d was constitutively associated
with PPRE 3, 4 and 5 among the five PPREs identified in silico and
tested in transactivation assays (Fig 3A, C), but p300 was recruited
by PPARb/d only upon GW501516 activation. Thus, ligand activa-
tion appeared to be necessary for PPARb/d to regulate Src gene
expression (Fig 3E), as for Tgfb1 (supplementary Fig S6).
Collectively, these observations demonstrated that UV induced
PPARb/d expression and activity. This activity in turn directly
increased Src gene and protein expression, results that define Src as
a novel PPARb/d target gene.
PPARb/d enhances the Src-dependent EGFR/MAPK Erk1/2
signalling pathway in response to UV
UV irradiation activates the EGFR/MAPK Erk1/2 pathway via Src
(Bode & Dong, 2003; Fritsche et al, 2007), a key mechanism in skin
photocarcinogenesis in mice and humans (Rho et al, 2011). The
possibility that PPARb/d activates not only Src but also the entire
Src/EGFR/Erk1/2 downstream pathway was tested next in various
PPARb/d and Src gain- and loss-of-function models. Src and Erk1/2
phosphorylation upon UV treatment was higher in wild-type than in
PPARb/d/ primary keratinocytes (supplementary Fig S7), con-
firming the importance of PPARb/d activity for UV-dependent full
activation of Src/Erk1/2. KD of PPARb/d in HaCaT cells consistently
abolished UV-induced activation of the EGFR/Erk1/2 pathway
(Fig 4A) (supplementary Fig S8), as did the absence of PPARb/d in
skin in vivo (Fig 4B, C). Conversely, activation of PPARb/d by its
agonist GW501516 enhanced the UV-induced phosphorylation of
EGFR (Tyr845) and Erk1/2 in HaCaT cells (Fig 4A, D). Importantly,
this action of PPARb/d completely depended on Src activity because
Src loss of function, either by pharmacological inhibition using a
PP2-specific Src family kinase inhibitor or Src KD by siRNA (supple-
mentary Fig S8), prevented an increase in EGFR and Erk1/2 phos-
phorylation (Fig 4A, D). Taken together, these observations provide
evidence in support of a PPARb/d-dependent UV stimulation of the
entire Src/EGFR/Erk1/2 signalling pathway. Finally, Ets1, whose
expression is stimulated by activated Erk1/2 (Fitsialos et al, 2007),
was enhanced in the UV-irradiated dorsal skin of wild-type mice
only (Fig 4E).
Wild-type and Pparb/d/ mice were then topically treated with
the PPARb/d antagonist GSK0660 prior to acute UV irradiation.
The UV-induced expression of two PPARb/d target genes,
Plin2 and Tgfb1, was prevented by GSK0660 (Fig 5A, B), which also
abolished the increase in Src gene and protein expression (Fig 5C,
D), resulting in both decreased phosphorylation levels of EGFR and
Erk1/2 (Fig 5D) and stimulation of Ets1 (Fig 5E). Interestingly, the
drug did not affect expression of the pro-inflammatory mark-
ers Ptgs2 (Cox2) and Il6 (supplementary Fig S9A, B) or
of Pparc and Ppara (supplementary Fig S9C, D). However, UV-
induced Pparb/d upregulation was abolished, suggesting a positive
feedback loop in PPARb/d expression, possibly involving Src
(Fig 5F). Taken together, these observations identified PPARb/d as
a positive regulator of a major pathway in skin carcinogenesis via
its effect on Src expression and activity.
PPARb/d coordinates a pro-tumoural gene program in advanced
actinic keratosis
Skin tumour growth is associated with increased proliferation and
migratory potential of keratinocytes, and in this process, Src pro-
motes epithelial cell dedifferentiation during the epithelial-to-mesen-
chymal transition (EMT). The EMT might also be regulated by other
Figure 2. PPARb/d promotes Src expression in irradiated skin.
A Src, Fyn and Yes mRNA expression by RT-PCR in acutely (Ac-UV, +) and non-irradiated () dermis and epidermis of Pparb/d+/+ and Pparb/d/ mice. The value from
irradiated dermis of Pparb/d/ mice was set to 1. Means  SEM are presented (n = 6 mice/genotype/group). Data are representative of three independent
experiments; p-values are, from top to bottom and from left to right, ***p = 0.0001, ***p = 0.0005, **p = 0.01, **p = 0.008 for Src; ***p = 0.0008, *p = 0.017,
***p = 0.0009 for Fyn; ***p = 0.0004, ***p = 0.0006, ***p = 0.0005, ***p = 0.0004, ***p = 0.0008, ***p = 0.0001, ***p = 0.001 for Yes calculated by two-tailed
Student’s t-test.
B Right, immunoblot of total Src in Ac-UV and non-irradiated skin of Pparb/d+/+ and Pparb/d/ mice. One of three independent experiments is shown (n = 6 mice/
genotype/group). GAPDH was used as loading control; IB, immunoblot; left, quantification of the immunoblot (right) of total Src in Ac-UV and non-irradiated skin
of Pparb/d+/+ and Pparb/d/ mice. Values are normalized to GAPDH, n = 3 mice/group; from left to right, **p = 0.010, 0.009, t-test.
C Src mRNA levels in non-tumoural skin of chronically irradiated (Ch-UV)Pparb/d+/+ mice and Pparb/d/ mice. Value from irradiated skin of Pparb/d/ was set to 1.
Means  SEM are given for 13 Pparb/d+/+ and 9 Pparb/d/ mice; *p = 0.035, t-test.
D Left, quantification of Src protein from the immunoblot (right) normalized to GAPDH (n = 5); **p = 0.009, t-test. Right, immunoblot of Src levels in Ch-UV non-
tumourigenic skin of Pparb/d+/+ and Pparb/d/ mice (n = 5). One of three independent experiments is shown.
E Representative pictures of Src immunohistochemistry in Ch-UV skin of 13Pparb/d+/+ and 9 Pparb/d/ mice. Scale bars, 50 lm.
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direct or indirect PPARb/d-modulated signalling pathways such as
the Tgfb1/SMAD pathway, which could act on Src expression
(Glick, 2012; Han et al, 2005; Hoot et al, 2008; Martins et al, 2009;
Nakamura & Tokura, 2011; Newkirk et al, 2007). Thus, we exam-
ined the ability of PPARb/d to enhance this transition by measuring
expression of EMT markers in actinic keratosis with moderate atypia
(grade II) of wild-type and Pparb/d/mice, including growth fac-
tors, transcription factors, cytoskeletal and cell surface markers,
extracellular matrix proteins and regulators (Fig 6A). The expres-
sion of many of these markers was higher in wild-type mice than
in Pparb/d/ mice, suggesting that the wild-type advanced grade
actinic keratosis presented a higher risk for premalignant progres-
sion. Results of basement membrane analysis using laminin 332
(a3b3c2) immunofluorescence supported this hypothesis (supple-
mentary Fig S10A). The basement membrane between the basal
keratinocyte layer and the adjacent stroma exhibited a clear lining
of laminin 332 in Pparb/d/ actinic keratosis with moderate atypia
(grade II) whereas laminin 332 deposition was more diffuse and
thicker in lesions of wild-type mice, reflecting perturbations of the
basal layer. The proximity ligation assay (PLA) showed that these
laminin 332 infiltrates in the basal and suprabasal epidermal layers
in wild-type mice could bind b4 integrin (Fig 6B, red positive signal
quantified in Fig 6D) and transduce signal via Rac1 (Fig 6C, red
positive signal quantified in Fig 6D). These observations were con-
sistent with the increased expression compared to Pparb/d/ mice
of EMT markers in wild-type grade II actinic keratoses, which dis-
played a higher level of proliferating keratinocytes and more intense
Keratin 13 staining, an early marker of malignant progression sus-
ceptibility (supplementary Fig S10B and S11). Moreover, histologi-
cal grading of SCCs from wild-type and Pparb/d/mice according
to the Broders’ classification (Broders, 1921) showed that wild-type
mice developed more advanced SCCs (Fig 6E) (supplementary Fig
S12). However, because of the conditions imposed by the Veterinary
Office (see Material and Methods for details), it was not possible to
obtain more advanced UV-induced skin tumours (Grade IV accord-
ing to Broders’ classification) to observe metastatic SCCs. Interest-
ingly, EMT markers were also expressed at higher levels in grade II
SCCs from wild-type compared to Pparb/d/ mice at the mRNA
and protein levels. N-Cadherin staining confirmed this result (sup-
plementary Fig S13).
Collectively, these observations suggested that keratinocytes of
wild-type mice were more likely to invade the surrounding stroma.
This characteristic represents a higher risk of malignant conversion
in these mice compared to the Pparb/d/ mice.
Correlation between PPARb/d and Src expression in various
human carcinomas
We wished to investigate whether the proto-oncogene Src is also a
PPARb/d target in human SCC. Interestingly, the levels of SRC and
PPARB/D expression were highly and significantly correlated in
these tumours (Fig 7A), as were the expression levels of PPARB/
D andTGFB1 and MMP19, respectively, and to a lesser extent,
MMP2, VEGFA, VIM and SNAI1 (Fig 7B, C) (supplementary Fig
S14A–D). These data suggested that, as in UV-irradiated mouse skin,
PPARb/d regulates SRC expression in human SCC, which is corre-
lated with the expression of EMT markers.
To further examine the underpinnings of these observations, we
investigated the relationships among SRC, TGFB1 and PPARB/
D expression levels in human carcinomas from various organs.
More specifically, we tested whether the degree of linear depen-
dency between SRC and TGFB1 mRNA levels (degree of correlation)
is influenced by the abundance of PPARB/D mRNA present in the
tumour (the significance of the interaction term TGFB1: PPARB/D
of the linear model SRC  TGFB1 + PPARB/D + TGFB1: PPARB/
D). This linear model was separately fitted to nine human tumour
types, including skin SCC (Fig 7–D–F) (supplementary Fig S14E–I).
The least square estimation of the model parameter revealed that
the TGFB1: PPARB/D interaction coefficient term was significantly
different from zero for lung (0.17 [0.06–0.29], 95% confidence inter-
val in square brackets) and ovarian (0.15 [0.04–0.27]) carcinomas
and oral squamous cell carcinoma (OSCC) (0.009 [0.003–0.014]).
Combining these nine independent interaction coefficients into a
random effects model, a method commonly used in statistical meta-
analysis, produced a significant summarized interaction coefficient
(0.081 [0.014–0.146]; Fig 7F). Results for SCC show that patients
with aPPARB/D mRNA abundance lower than the median value had
an absence of linear dependency between SRC and TGFB1 (p =
0.75; Fig 7D) but that those with a PPARB/D abundance above or
equal to the median of the dataset showed a significant linear rela-
tionship (p = 0.0336; Fig 7E). Results with the ovarian carcinoma
Figure 3. Src is a direct PPARb/d target gene.
A Schematic structure of the murine Src gene. Untranslated and translated exons of Src-001 transcript and position of primers used for 5′ RACE are depicted as
indicated. GSP, gene-specific primer.
B Identification of the Src transcript isoform expressed in wild-type primary keratinocyte cultures treated with GW501516 (100 nM) for 24 h (lane 1) and total skin of
SKH-1 wild-type mice after acute irradiation (lane 2). In both samples, a major 650-bp product was obtained. Sequencing of the isolated DNA bands indicated that
the transcripts corresponded to the Src-001 transcript (ENSMUST00000029175).
C PPARb/d activity on wild-type or mutated PPREs in the Src promoter (supplementary Fig S5) via luciferase assays in NIH3T3 cells treated with GW501516 (300 nM) or
vehicle (DMSO). Fold inductions were calculated as the ratio of firefly luciferase to Renilla luciferase activity using DMSO-treated NIH3T3 cells transfected with a TK-
3PPRE construct designated as 1. Values are shown as the mean  SD (n = 3).p-values are, from left to right, ***p = 0.0002, 0.0003, 0.0001, 0.0032, 0.0001, 0.0008
calculated by two-tailed Student’s t-test. One of three independent experiments is shown.
D,E Representative results of ChIP experiments using anti-PPARb/d antibody (D) followed by re-ChIP with anti-p300 (E) performed in mouse keratinocytes (MKs)
downregulated for PPARb/d expression by siRNA [knockdown cells (KD)] or not (wild-type cells, WT) treated or not with GW501516. The results show a PCR
amplification of the PPRE3, 4 and 5 sites. Preimmune serum (p.i.) served as a control for ChIP. Primer sequences are given in supplementary Table S3. Data are
representative of n = 3 independent experiments.
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Figure 4. PPARb/d-dependent upregulation of Src expression enhances EGFR/Erk1/2 signalling upon UV exposure in vitro and in vivo.
A Immunoblots of Src, pTyr845 EGFR, total EGFR, pErk1/2 and total Erk1/2 levels from whole-cell lysates of HaCaT cells transiently transfected with control
(Ctrl), Pparb/d or Src siRNA, treated 24 h with GW501516 or DMSO, and then subjected to UVB radiation (40 mJ/cm2) before harvesting 30 min later. GAPDH was
used as a loading control. Data are representative of three independent experiments.
B,C Immunoblot of pTyr845 EGFR, total EGFR, pErk1/2 and total Erk1/2 levels in protein extracts from chronically irradiated (Ch-UV) (B) or acutely irradiated (Ac-UV) (C)
dorsal skin of Pparb/d+/+ and Pparb/d/ mice. Data are representative of three independent experiments.
D Immunoblot of pTyr845 EGFR, total EGFR, pErk1/2 and total Erk1/2 levels from whole-cell lysates of HaCaT cells treated with the PPARb/d agonist GW501516 or
DMSO for 24 h before UVB exposure (40 mJ/cm2) in the presence or absence of a Src family kinase inhibitor (PP2), and harvested 30 min later. Data are
representative of three independent experiments.
E Real-time RT-PCR of Ets1 mRNA expression in non-irradiated and Ac-UV dorsal skin of Pparb/d+/+ and Pparb/d/ mice. Data are representative of three
independent experiments for 12 Pparb/d+/+ and 12 Pparb/d/ mice; p-values are *p = 0.032, **p = 0.009 calculated by two-tailed Student’s t-test.
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Figure 5. Pharmacological inhibition of PPARb/d prevents UV-induced Src expression and Src-dependent activation of EGFR/Erk1/2 signalling in vivo. Dorsal
skin of Pparb/d+/+ and Pparb/d/ mice was topically treated with the PPARb/d antagonist GSK0660 or vehicle (Veh; 70%ethanol) prior to acute UV irradiation (Ac-UV); mice
were sacrificed 24 h later.
A–C Quantification of Plin2 (A), Tgfb1 (B) and Src (C) mRNA expression via real-time RT-PCR. Means  SEM are presented (n = 6 mice/genotype/group). Data are
representative of two independent experiments; p-values are *p = 0.0190, **p = 0.0066, ***p = 0.0004 for Plin2; *p = 0.0421, 0.0153 (from left to right) and
**p = 0.0098 for Tgfb1; *p = 0.0428, **p = 0.0098, ***p = 0.0045 for Src calculated by two-tailed Student’s t-test; ns, not significant.
D Immunoblot of total Src, EGFR, p-Tyr845 EGFR, Erk1/2 and p-Erk1/2 protein in extracts from dorsal skin of Pparb/d+/+ and Pparb/d/ mice. Data are
representative of two independent experiments (n = 12 mice/genotype/experiment).
E Quantification of Ets1 mRNA expression by real-time RT-PCR. Means  SEM are given (n = 6); p-values are *p = 0.0324 and **p = 0.0091, 0.082 (from left to
right) calculated by two-tailed Student’s t-test.
F Quantification of Pparb/d expression via real-time RT-PCR. Means  SEM are presented (n = 6 mice/genotype/group). Data are representative of two independent
experiments; p-values are **p = 0.0083 and ***p = 0.0006 calculated by two-tailed Student’s t-test; ns, not significant.
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and OSCC datasets led to similar inferences (supplementary Fig
S14F–I).
Thus, our statistical modelling provided evidence that the expres-
sion level of PPARB/D influences the degree of correlation
between SRC andTGFB1 levels across a wide variety of human car-
cinomas, an observation that supports our hypothesis of a direct
influence of PPARb/d on SRC and TGFB1 transcription. Taken
together, our observations and analyses indicate that PPARb/d regu-
lates SRC in human SCC, notably in skin SCC, and that this regula-
tion also occurs in carcinomas of various tissue origins, thus
revealing a broad pro-tumourigenic potential of PPARb/d
via SRC upregulation.
Discussion
Our study demonstrates that PPARb/d promotes skin cancer by
enhancing Src activity in response to UV radiation. UV is a skin car-
cinogen causing both DNA damage resulting in tumour initiation
and activation of signalling cascades that promote tumour develop-
ment (Devary et al, 1993; Matsumura & Ananthaswamy, 2004; Rho
et al, 2011). The signalling pathway involving the tyrosine kinase
Src, the tyrosine kinase receptor EGFR and the MAPK Erk1/2
cascade is activated during UV-induced skin inflammation and carci-
nogenesis, promoting initiation, progression and malignant conver-
sion. This pathway is therefore a target for epithelial cancer
prevention (Fritsche et al, 2007; Rho et al, 2011). Importantly, this
pathway and its cellular effects may also be modulated by other
PPARb/d-dependent or -independent signalling pathways, such as
Tgfb1/SMAD.
To date, the nuclear receptor PPARb/d has been less studied than
PPARa and PPARc, which are drug targets for the treatment of dysli-
pidemia and type 2 diabetes, respectively. Recently, the US Food
and Drug Administration released safety information linking pioglit-
azone, which targets PPARc, to increased risk for bladder cancer.
Although there is growing interest in developing PPARb/d agonists
to treat dyslipidemia, no PPARb/d compound has been brought to
market, and the role of this isotype in tumourigenesis has been
debated (Michalik et al, 2004; Peters & Gonzalez, 2009; Peters et al,
2012).
Our study has yielded the first insights into how PPARb/d pro-
motes UV-induced skin tumourigenesis (Fig 7G). In vivo UV
exposure increases PPARb/d expression at the transcriptional level
and its activity. Once activated, PPARb/d upregulates Src expression
and activity, which in turn, boosts EGFR/Erk1/2 signalling. Thus, in
our mouse model, PPARb/d sensitizes keratinocytes to UV, pro-
motes actinic keratosis development and progression, and stimu-
lates the expression of EMT markers that affect basement membrane
integrity. Importantly, PPARB/Dexpression and SRC, MMP19
and SNAI1 expression directly correlate in human skin SCC, which
may indicate a direct effect of PPARb/d on EMT initiation. Further-
more, our meta-analysis of PPARb/d activity in various epithelial
tumours, including human skin SCC, revealed a positive interaction
between PPARB/D expression levels and those of two of its tar-
gets, SRC and TGFB1. Interestingly, the identification of this relation-
ship in large independent datasets of various tumour types,
particularly in lung, colon and ovarian cancers known for their high
levels of Src expression and activity, strongly supports a regulatory
role for PPARb/d in human carcinomas. We speculate that early in
skin actinic keratosis formation, PPARb/d regulates Src and may act,
in concert with other genetic change, to promote tumour progression
by increasing keratinocyte migratory and proliferative properties. Our
data help to define the pro-carcinogenic properties of PPARb/d in skin
carcinoma and most likely in carcinomas from other tissue origins, as
well, and identify Src as a direct PPARb/d target gene, at least in
mouse.
In accordance with our observations, ErbB2 activation, in concert
with ErbB3 and ErbB4, leads to the expression of FABP5, an intra-
cellular lipid binding protein, which plays a crucial role in PPARb/d
transcriptional activation in the MCF7 cell line, suggesting that the
EGFR superfamily could also act upstream of PPARb/d to regulate
its activity in a model of breast cancer (Kannan-Thulasiraman et al,
2010). Although its consequences remain unknown, the expression
of PPARb/d has been reported to be increased in skin pathologies
such as the lesional skin of psoriatic patients (Romanowska et al,
2010; Westergaard et al, 2003) and in human skin biopsies of pre-
malignant and malignant skin carcinoma (Nijsten et al, 2005; Sertz-
nig et al, 2008). In the latter, increased PPARb/d expression has
been associated with a significant increase in microvessel density
and strongly correlates with the expression of COX2, an enzyme
implicated in skin carcinoma development (Trifan & Hla, 2003).
Interestingly, our previous findings of PPARb/d participation in
keratinocyte survival, proliferation and migration during skin
wound healing (Tan et al, 2007) are somewhat analogous to the
Figure 6. PPARb/d upregulates pro-tumoural marker gene expression and laminin 332 deposition in actinic keratosis, enhancing SCC progression.
A mRNA expression of epithelial-to-mesenchymal transition (EMT) markers in 20 actinic keratoses with moderate atypia (grade II) of Pparb/d+/+ and Pparb/d/ mice
by real-time RT-PCR. Means  SEM are presented; p-values are **p = 0.0077 (Tgfb1), ***p = 0.0009 (Krt13), *p = 0.046 (Vim), *p = 0.045 (Snai1), *p = 0.032 (Snai2),
*p = 0.028 (Gsc), **p = 0.009 (Itgav), *p = 0.025 (Itga6), *p = 0.022 (Itgb1), *p = 0.013 (Itgb6), *p = 0.035 (Cadh12), *p = 0.020 (Col7a1), *p = 0.035 (Mmp19),
*p = 0.025 (Lama3), *p = 0.043 (Mmp2) calculated by two-tailed Student’s t-test. The full gene names are given in supplementary Table S2.
B Representative immunofluorescence staining of PLA experiments for laminin 332/b4 integrin (red spots) in actinic keratosis with moderate atypia (grade II) sections
from Pparb/d+/+ and Pparb/d/ mice. DAPI, blue. Scale bars, 50 lm.
C Representative immunofluorescence staining of PLA experiments for b4 integrin/Rac1 (red spots) and laminin 332 in actinic keratosis with moderate atypia (grade II)
sections from Pparb/d+/+ and Pparb/d/ mice. DAPI, blue. Scale bars, 50 lm.
D Quantification of PLA staining. Average number of PLA signals (red spots) per nucleus from n = 10 actinic keratoses with moderate atypia sections/genotype
(*p = 0.024, t-test).
E Actinic keratosis (AK) with grading of cellular atypia (mild, grade I; moderate, grade II; severe, grade III) and SCC distribution in 25 tumours collected from
each Pparb/d+/+ and Pparb/d/ mouse graded histologically in a blinded manner according to Rowert-Huber et al and to the Broders’ classification, respectively.
◂
EMBO Molecular Medicine Vol 6 | No 1 | 2014 ª 2013 The Authors
EMBO Molecular Medicine PPARb/d promotes skin cancer via Src Alexandra Montagner et al
90
F 
G
A
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 0.2 0.4 0.6 0.8 1 1.2 1.4
r=0.85
coef=1.83
p=9.2e-4
M
M
P
19
m
R
N
A
 e
xp
re
ss
io
n
PPARB/D mRNA expression
C
PPARB/D mRNA expression
S
R
C
m
R
N
A
 e
xp
re
ss
io
n
1.2
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 0.2 0.4 0.6 0.8 1
r=0.74
coef=0.70
p=0.014
0
0.2
0.4
0.6
0.8
1
1.2
0 0.2 0.4 0.6 0.8 1 1.2 1.4
r=0.77
coef=0.60
p=0.006
PPARB/D mRNA expression
TG
FB
1 
m
R
N
A
 e
xp
re
ss
io
nB
lo
g 2
S
R
C
log2 TGFB1
lo
g 2
S
R
C
log2 TGFB1
D 
UVB EGFR
Y845
Yp
p
Yp
skin tumor 
formation/progression
EMT markers
(Snai1/2, Tgfβ1,…)
Erk1/2p p
SrcPPAR /
Y416p
Plasma membr.
nucleus
cytoplasm
inactive active
Y845
Pparβ/δ
Src Src
p
(PPREs)
8.35 8.40 8.45 8.50 8.55 8.60
9.0
9.1
9.2
9.3
9.4
9.5
9.6
r=-0.050
coef=-0.23
p=0.75
8.34 8.36 8.38 8.40
9.0
9.2
9.4
9.6
9.8
10.0
r=-0.46
coef=4.78
p=0.0336
E 
N Effect Lower 95% Upper 95% Weights (%)
LU 121 0.17 0.06 0.29 13.31
LI 41 0.02 -0.27 0.30 4.12
BR 344 0.07 -0.01 0.15 16.77
CO 277 0.16 0.00 0.32 9.26
OV 202 0.15 0.04 0.27 13.39
PR 67 -0.41 -0.83 0.01 2.11
KI 265 0.07 0.00 0.13 18.39
OSCC 97 0.01 0.00 0.01 22.63
SSC 42 6.76 -0.01 13.60 0.01
Summary 1456 0.08 0.02 0.15 100.000
Figure 7.
ª 2013 The Authors EMBO Molecular Medicine Vol 6 | No 1 | 2014
Alexandra Montagner et al PPARb/d promotes skin cancer via Src EMBO Molecular Medicine
91
tumour-development functions described in the current investiga-
tion, providing a further example of the molecular parallels between
wound repair and cancer. It is intriguing to note that we and others
have also described PPARb/d as a pro-differentiating factor in kerat-
inocytes (Burdick et al, 2007; Peters & Gonzalez, 2009; Tan et al,
2001). Similarly, a pro-differentiation function has been attributed
to the MAPK-Erk1/2 pathway in keratinocytes, a pathway that is
clearly pro-carcinogenic in skin tumours (Rho et al, 2011; Seo et al,
2004). These apparently contradictory pro-differentiation and pro-
carcinogenic roles may be due to different environmental stimuli
and/or genetic contexts, which could lead to different kinetics and
amplitude of Erk1/2 stimulation, switching the spectrum of their tar-
get proteins. This model could also accommodate a role for PPARb/
d. Indeed, increasing evidence suggests that physiological or patho-
logical contexts, including the genetic background, drive PPARb/d
functions and might influence the extracellular signals, endogenous
ligands produced, ligand-binding protein expression and post-trans-
lational modifications. These parameters are likely to affect the level
and activity of PPARb/d and the expression pattern of its numerous
target genes.
This hypothesized complexity could explain the between-study
discrepancies regarding the role of PPARb/d in skin carcinogenesis.
For example, Kim et al explored the anti-cancer properties of
PPARb/d in skin using DMBA/TPA-induced carcinogenesis, a con-
text in which tumour development was more severe in Pparb/d/
 mice than in wild-type animals, suggesting that PPARb/d attenu-
ates the development of chemically induced skin cancer (Kim et al,
2004). Inhibition of keratinocyte proliferation was thought to medi-
ate this effect of PPARb/d mainly via the activity of protein kinase
Ca. However, in transgenic mice that over-express protein kinase
Ca, the susceptibility to DMBA/TPA-induced skin tumourigenesis
was not affected (Cataisson et al, 2003; Wang & Smart, 1999). More-
over, induction of skin cancer by DMBA/TPA involves different
molecular mechanisms from those associated with human skin can-
cer attributable to chronic UV exposure (Boukamp, 2005; Matsum-
ura & Ananthaswamy, 2002). Notably, tumour initiation with a
unique topical sub-carcinogenic dose of a genotoxic carcinogen
(DMBA) primarily induces Ha-Ras-activating mutations, whose
frequency reaches only 10–20% in human SCCs and basal cell carci-
nomas, reflecting a marginal contribution of this oncogene to these
carcinomas (Campbell et al, 1993; Lieu et al, 1991; Pierceall et al,
1991). In this context, our proposed model pathway could be
masked by such Ha-Ras-activating mutations, rendering the MAPK
Erk1/2 activation upstream independent of Src/EGFR stimulation.
Moreover, this apparent controversial function of PPARb/d in
cancer development is also illustrated in other cancer types for
which several studies have suggested an attenuation of carcinogene-
sis by PPARb/d, while others support a tumour-promoting role
(reviewed in Michalik et al, 2004; Peters & Gonzalez, 2009; Peters
et al, 2012). For instance, studies indicate that colon carcinogenesis
is exacerbated in the absence of PPARb/d expression and/or that
ligand activation of PPARb/d attenuates tumourigenesis (Harman
et al, 2004; Hollingshead et al, 2008; Reed et al, 2004). In contrast,
other studies have shown that genetic disruption of PPARb/d inhibits
colorectal tumourigenesis and that ligand activation of PPARb/d pro-
motes tumourigenesis (Gupta et al, 2004; Park et al, 2001; Wang
et al, 2006; Zuo et al, 2009). Many of these studies are based on
PPARb/dmRNA or protein expression levels, which do not necessar-
ily reflect the ligand-dependent activity of the receptor. Interestingly,
the expression of both PPARb/d and COX-2 in tissues of colorectal
cancer patients leads to liver metastases, a condition associated with
poor prognosis (Yoshinaga et al, 2011). PPARb/d gene expression is
upregulated in patients with non-small cell lung cancer and corre-
lated with the expression of VEGFA and COX2. Moreover, cell lines
with relatively high PPARb/d activity (e.g. H441 and H358) exhibit
proliferative and pro-survival responses, which are absent or mini-
mal in cells with low levels of the receptor (e.g. A549) (Genini et al,
2012). In addition, PPARb/d, via its regulation of ANGPTL4 gene
expression, is suggested to be implicated in MDA-MB-231 cancer cell
invasion into a three-dimensional matrix (Adhikary et al, 2012).
These findings suggest a tumour-promoting function for PPARb/d, in
accordance with our data on skin carcinoma, and this diversity of
PPARb/d actions underscores the need for more work in mouse
models and human tissue samples to decipher the complex PPARb/d
functions in tumourigenesis. An illustration of this complexity is the
importance of the isotype and expression levels of fatty acid-binding
proteins in directing the same ligand towards RAR or PPARb/d. The
latter promotes the pro-carcinogenic function of PPARb/d in breast
tumour development (Kannan-Thulasiraman et al, 2010; Schug
et al, 2007; Schug et al, 2008).
Figure 7. PPARB/D and SRC mRNA expression are correlated in human skin SCC and in other types of human carcinomas.
A–C Correlation between PPARB/D and SRC (A), PPARB/D and TGFB1 (B) and PPARB/D and MMP19 (C) expression as assessed via real-time RT-PCR of RNA extracted
from human SCC biopsies (n = 9). p-values are calculated by two-tailed Student’s t-test.
D,E Interaction between TGFB1 and PPARB/D underlies SRC expression levels. All 42 SCCs were sorted by PPARB/D expression. Samples with either the highest (n = 21;
top 50% of the samples) or lowest (n = 21, bottom 50% of the samples) PPARB/D levels were identified. (D) Least squares regression
between TGFB1 and SRC expression levels in samples with the lowest PPARB/D expression. The black line represents the least square fit. The observed linear
regression coefficient (0.23) was not significantly different from zero (Student p-value = 0.75). (E) Linear regression between TGFB1 and SRC levels in the 21
tumour samples with the highest PPARB/D expression revealed a significant linear relationship.
F Table presenting the interaction coefficient b3 (estimate) and its 95% confidence interval for the linear model SRC  b0 + b1TGFB1SRC + b2PPARB/
D + b3TGFB1SRC: PPARB/D. The summarized meta-analysis of the interaction coefficient was estimated using a random effects model.
G Model of the molecular function of PPARb/d in UV-induced skin tumours. UV irradiation induces PPARb/d gene expression and activation. Once activated, PPARb/d
drives the expression of Src, which correlates with an increased Src protein level and higher kinase activity. This activity leads to the activation of the Src-
dependent EGFR/Erk1/2 signalling pathway, which drives the expression of genes involved in the epithelial-to-mesenchymal transition (EMT). In coordination with
other PPARb/d-dependent or -independent mechanisms and/or genetic defects, this mechanism enhances skin tumour formation and progression upon UV
exposure, identifying PPARb/d as a putative inducer of carcinoma.
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Src-centred investigations have thus far concentrated on the
mechanisms of post-translational regulation of its kinase activity,
but little is known regarding the factors regulating the expression of
its gene. The observation that PPARb/d stimulates Src expression
sheds new light on this powerful oncogene, and interest is growing
in Src as a potential therapeutic target in skin carcinoma treatment
(Serrels et al, 2009). Our study also raises fundamental biological
questions related to cancer therapy. Inhibitors of Src are used in the
treatment of many carcinomas but are associated with side effects
(Kopetz et al, 2007). Because Src is a target of PPARb/d, specific
antagonists of the receptor might be considered for the treatment of
such cancers and/or prevention of malignant progression of actinic
keratosis. Given that PPARb/d is a promising molecular target in the
prevention and treatment of metabolic diseases such as dyslipide-
mia, obesity and diabetes, we suggest a careful evaluation of the use
of high-affinity PPARb/d agonists such as GW501516, which is cur-
rently in phase IV clinical trials for the treatment of dyslipidemia
(Ooi et al, 2011).
Materials and Methods
Animal model and UVB irradiation
SKH-1 hairless mice (Charles River) were crossed with SV129/BL6/
J Pparb/d wild-type or Pparb/d/ mice to obtain SKH-1/Pparb/
d wild-type and SKH1/Pparb/d/ mouse strains. Mice were housed
in quarters with a 12/12-h light/dark cycle and maintained with
water and food ad libitum. For acute and chronic UV exposure, mice
were UV irradiated on their backs with a GL40E 40W tube (SNEE),
which emits most of its energy within the UVB range (90%; emission
spectrum 280–370; 10% UVA). Doses of UVB (312 nm) and UVA
(370 nm) were monitored using an appropriate radiometer.
For acute exposure, female SKH-1 wild-type and Pparb/d/
mice ages 10–12 weeks were irradiated on their backs with the UV
lamp. UVB radiation emission was controlled using a radiometer
until a dose of 120 mJ/cm2 was delivered. Non-irradiated age-
matched mice were used as controls. Twenty-four hours after UV
irradiation, animals were sacrificed using CO2 gas, following by the
acquisition of dorsal skin samples that were directly frozen in liquid
nitrogen or prepared for histological analysis. For GSK0660 treat-
ment, 200 ll of GSK0660 (625 lg/ll in 70% ethanol; Sigma, G5797)
was applied topically on the back 1 h prior to UV exposure.
For chronic treatment, animals were irradiated on their backs
three times per week with 70 mJ/cm2 of UVB, which was monitored
using a radiometer. The time of tumour appearance, number and
size were monitored twice per week. Mice with one tumour reach-
ing 9 mm in diameter were sacrificed using CO2 gas in accordance
with the requirements of the Veterinary Office of the Canton Vaud
(Switzerland) and Federal Swiss Veterinary Office Guidelines. Non-
irradiated aged-matched mice were simultaneously used as controls
and handled in the same fashion as the irradiated animals. Dorsal
tumours or non-tumoural irradiated skin samples were then
obtained and prepared as described above.
Tumour grading
Mouse skin tumours were paraformaldehyde-fixed and paraffin-
embedded. Tissue sections (5 lm) were stained with hematoxylin/
eosin. Histological analysis of actinic keratosis and tumour
classification were performed in a blind manner by a pathologist.
SCCs were classified according to the Broders’ classification based
on the degree of SCC keratinization and of keratinocyte differentia-
tion (Broders, 1921). This classification is as follows: SCC Grade I:
75% keratinocytes are well differentiated; SCC Grade II: >50%
keratinocytes are well differentiated; SCC Grade III: >25% keratino-
cytes are well differentiated and SCC Grade 4: <25% keratinocytes
are well differentiated. Actinic keratoses were defined histologically
and classified as grade I, II or III based on the degree of cytological
atypia of epidermal keratinocytes and involvement of adnexal struc-
tures according to Rowert-Huber et al (Rowert-Huber et al, 2007).
Representative pictures of actinic keratosis and SCCs are presented
in supplementary Fig S12.
Human skin biopsies
Cutaneous SCC samples were obtained anonymously from the
Department of Dermatology, University Hospital of Lausanne, Swit-
zerland. Normal skin was from healthy adult volunteers or from the
edges of skin tumours. SCC was diagnosed by experienced patholo-
gists. Informed consent for research was obtained prior to routine
diagnostic services. All samples include the dermis and the epider-
mis.
Preparation of expression data
We used expression microarrays from the Expression Project for
Oncology Consortium (Affymetrix human genome HG-U133 plus 2.0
arrays) and from the Gene Expression Omnibus (accession code:
GSE2109). Only the following tumour types were considered: breast
(n = 344), lung (n = 121), liver (n = 41), pancreas (n = 14), colon
(n = 277), ovarian (n = 202), prostate (n = 67) and kidney
(n = 259). Other tumour types were excluded because of low sam-
ple numbers at the time of download.
Gene expression data were normalized with the robust multi-
array method implemented in the library affymetrix. Three selection
criteria were applied to probe sets: annotation to a defined Entrez
gene, standard deviation of normalized expression greater than 0.1,
and characterization as the most variable probe set for a given En-
trez gene. The normalized, log-transformed expression measures
were used for the analysis. For the OSCC dataset, because two data-
sets were available from the GEO database, optimal probe set selec-
tion among features mapped to TGFB1, SRC and PPARB/D was
performed with the GSE30784 dataset and then applied in the
GSE41613 (Chen et al, 2008; Lohavanichbutr et al, 2013). Only
results obtained with the GSE41613 were considered in the main
analysis. For the SSC dataset, the GSE32628 was taken using the
normalized values provided by the contributor (Hameetman et al,
2013).
All data were analysed in the R programming environment
(2.9.1). Linear regression models were used to assess the relation-
ships between gene expression levels using additive and multiplica-
tive models (interactions). Linear models were applied separately to
each tumour type. A meta-analysis of the interaction coefficient esti-
mates for the various tumour types was performed using a random
effect model.
Src cDNA isolation, polyA-tailing and 5′ RACE
To identify Src transcript isoform(s) induced by PPARb/d in skin
and keratinocytes, Src mRNA was specifically reverse transcribed
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with Superscript II (Invitrogen) using 50 ng of primer GSP1 (Gene
Specific Primer 1, primer sequence given in supplementary Table
S2) from 5 lg of total RNA (extraction with TRIzol, Invitrogen) from
a culture of wild-type primary keratinocytes treated for 24 h with
GW501516 (100 nM) or total skin from wild-type SKH-1 mice
acutely irradiated and sacrificed 24 h later. After treatment with
RNase H (New England Biolabs) for 20 min at 37°C, first-strand Src
cDNA was purified (Macherey-Nagel) before a polyA-tailing reaction
in the presence of Tdt (Promega) and ATP. A first, PCR was per-
formed using Frohmann and GSP2 (Gene Specific Primer 2) primers
(Fig 3; sequences given in supplementary Table S2) using Herculase
II Fusion DNA Polymerase (Agilent Technologies) according to the
manufacturer’s instructions. A nested PCR was then performed with
Q0 and GSP3 (Gene Specific Primer 3) primers (Fig 3; sequences
given in supplementary Table S2) using Herculase II Fusion DNA
Polymerase (Agilent Technologies). PCR products were then puri-
fied (Macherey-Nagel) and loaded onto agarose gels for identifica-
tion of the Src transcript(s). GSP1, GSP2 and GSP3 primers were
designed to specifically amplify a region corresponding to Src-001,
Src-007, Src-005, Src-006 or Src-201 transcripts described in Ensem-
bl. The DNA bands revealed were then excised and purified before
sequencing.
PPRE subcloning, mutagenesis and promoter activity assay
To analyse Src promoter activity, various regions of the promoter
(annotated from the transcriptional start site in the mouse genome)
were inserted into the plasmid vector pGL4 (Promega, E8421) to gen-
erate pGL4-PPRE1, pGL4-PPRE2, pGL4-PPRE3, pGL4-PPRE4 and
pGL4-PPRE5. pGL4-PPRE mutant plasmids carried mutated PPRE
sequences introduced with the QuikChange Site-Directed Mutagene-
sis Kit (Stratagene). Primers used for mutagenesis are given in sup-
plementary Table S1. NIH3T3 cells were plated the day before
transfection in 12-well plates. Either 0.8 lg of wild-type or mutated
pGL4-PPRE or 0.5 lg of 3 9 -PPRE-TK-Luc (gift from R. Evans) plas-
mids were introduced into the cells via Superfect (Qiagen), together
with 0.5 lg of pSG5-mouse-PPARb/d and 0.025 lg of a Renilla lucif-
erase construct. After overnight serum starvation, transfected cells
were treated for 24 h with GW501516 (100 nM) and then lysed in
1 9 passive lysis buffer and analysed for dual luciferase activity fol-
lowing the manufacturer’s instructions (Promega). Relative lucifer-
ase activity was calculated as the ratio of firefly to Renilla luciferase
activity. Data represent means  standard deviations of relative
luciferase activities for DMSO performed in triplicate.
Immunoblotting
Cells and tissue samples were lysed in TNE buffer containing
20 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 10% glycerol,
1% NP-40, 10 lg/ml leupeptin, 10 lg/ml aprotinin and 1 mM
Na3VO4. After quantification, proteins were separated by SDS-PAGE
and subjected to immunoblotting. All primary antibodies were incu-
bated overnight in 1 9 Tris-buffered saline plus 0.1% Tween-20
and 5% bovine serum albumin at a dilution of 1:1000 except where
indicated otherwise. Cell Signalling was the source for the following
antibodies: Src (2123), phospho-Tyr845 EGFR (6963), EGFR (4267),
phospho-Erk1/2 (4370), Erk1/2 (9102), b-Catenin (8480), phospho-
Ser675 b-Catenin (4176), Slug (9585) and GAPDH (2118). Anti-b-
tubulin and N-Cadherin were purchased from BD Biosciences
(556321) and Millipore (04-1126; 1/50 000), respectively.
ChIP and re-ChIP
ChIP experiments were carried out with modifications of the experi-
mental setup described by Tan et al (Tan et al, 2004). Briefly, chro-
matin was crosslinked using 0.5% formaldehyde for 10 min at 37°C
and sonicated in SDS lysis buffer (1% SDS, 10 mM EDTA and
50 mM Tris-HCl, pH 8.1) to obtain crosslinked DNA that measured
200–500 bp in length. Approximately 10% of the supernatant was
retained as input, while the remaining amount was processed with
the ChIP using anti-PPARb/d antibody (4 lg; SC-7197, TransCruz
Grade; Santa Cruz), and complexes were pulled-down by Protein A/
G (Santa Cruz, CA, USA). Re-ChIP was performed by subsequent
probing with anti-p300 antibody (4 lg; 05–257, Millipore); DNA
fragments were reverse crosslinked at 65°C for 6 h. The pre-immune
complex served as negative control. The ChIP primer sequences are
listed in supplementary Table S3. Downregulation of PPARb/d in
MK cells was performed using a siRNA construct against
mouse Pparb/d (L-042751-01, Thermo Scientific), as recommended
by the manufacturer (Dharmacon, Thermo Scientific). Briefly, MK
cells were seeded in 10-cm dishes and transfected with 25 nM of
siRNA in DharmaFECT1 transfection reagent (T-2001-03, Thermo
Scientific). MK cells transfected with scrambled siRNA were used as
controls. The efficiency of KD was tested by real-time PCR 48 h later
(supplementary Fig S5E).
Immunohistochemistry and immunofluorescence
Src, Ki67 and Keratin 13 staining was performed on tissue sections
(5 lm) from paraformaldehyde-fixed, paraffin-embedded skin.
Briefly, sections were quenched with 3% H2O2. Ki67 (Abcam,
15580) staining was performed as described by the manufacturer.
For Src and Keratin 13 staining, the antigen-retrieval step was
achieved in 0.1 M citrate buffer [pH 6] via microwave. After wash-
ing, sections were incubated in normal goat serum 1% for 30 min
and probed with Src (Cell Signalling; 2109; 1:250) and Keratin 13
(Abcam; ab92551; 1:100) antibodies overnight at 4°C or at room
temperature in blocking buffer, respectively. After washing, sections
were incubated for 30 min with anti-rabbit horseradish peroxidase
secondary antibody (EnVision+ rabbit-HRP; Dako; K4002). Visuali-
zation was performed with diaminobenzidine substrate (Vector
Labs) for 14 min before being counterstained with Mayer hematoxy-
lin and mounted. Keratin 10 and Keratin 14 co-staining and N-Cadh-
erin staining were performed as described above with the following
modifications. Tissue sections were probed with Keratin 10 (Progen;
GP-K10; 1/200), Keratin 14 (Covence; PRB-155P; 1/1000) or
N-Cadherin (Millipore; 04-1126; 1/50) overnight at 4°C, washed,
and then incubated 30 min at room temperature with Goat anti-gui-
nea-pig A488 (Molecular Probes; A11073; 1/200) and Goat anti-rab-
bit A568 (Molecular Probes; A21069; 1/1000), for Keratin 10/
Keratin 14 co-staining or Goat anti-rabbit A568 (Molecular Probes;
A21069; 1/1000) for N-Cadherin staining. After washing, counter-
staining was performed with 4′,6-diamidino-2-phenylindole (DAPI)
for 5 min at RT.
Double staining for laminin 332 and pan-Cytokeratin was per-
formed from OTC-embedded frozen skin samples. Briefly, sections
were defrosted and incubated in acetone for 10 min, washed and
blocked for 1 h in 1% normal goat serum/5% bovine serum albu-
min. Sections were probed overnight at 4°C with anti-laminin 332
(Abcam; 14509; 1:200) and anti-pan-Cytokeratin (BMA-T1341;
1:250) in blocking buffer. After being washed, sections were
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incubated for 30 min with anti-mouse STAV-Cy3 (Zymed; 43-4315;
1:1800) and anti-rabbit A488 (Molecular Probes; A111034, 1:2000)
diluted in blocking buffer. Sections were then washed three times
and incubated 5 min with DAPI (Sigma; D95542; 1:5000) and
washed again before being mounted.
PLA and immunofluorescence
PLA experiments were performed in accordance with the manufac-
turer’s protocol (Olink Biosciences, Sweden) using pairs of antibod-
ies targeting the protein–protein interactions of interest. The
antibodies were laminin 332 (1:20; Abcam, ab14509), active integrin
b4 (Abcam, ab29042; 1/50) and Rac1 (Abcam, ab97732; 1/20). PLA
images were taken using the LSM 710 confocal microscope (Carl Ze-
iss, Germany) with the Plan-Apochromat 40 9 /1.4 oil differential
interference contrast objective. Analyses were performed with the
ZEN 2009 Light Edition software (Carl Zeiss, Germany). Quantifica-
tion of PLA signals was performed with BlobFinder version 3.2
(Allalou & Wahlby, 2009). Immunofluorescence for laminin 332 (1/
250) was performed after PLA for integrin b4 and Rac1 as previously
described.
Epidermis and dermis separation for RNA extraction
Epidermis and dermis were prepared from whole dorsal skin of
acutely irradiated mice according to the protocol developed by
Clemmensen et al (Clemmensen et al, 2009), with some modifica-
tions. After dorsal skin harvest, adipose tissue was removed with a
scalpel on ice, and the skin was cut into small pieces (1–2 mm) and
immediately incubated for 15 min at RT in ammonium thiocyanate
3.8% in 1 9 phosphate-buffered saline. Epidermis and dermis were
then separated mechanically with forceps in TRIzol. After RNA
extraction and quality control by Bioanalyser, RT-PCR and qPCR
were performed as described below to generate cDNA. Specific
markers of the epidermis (Keratins 10 and 14) and dermis (Collagen
4a1) compartments were tested by qRT-PCR to check the proper
separation of the two in each experiment (supplementary Fig S2D).
Statistics summary
Unless indicated otherwise, all data are presented as the
means  standard errors of the mean, and statistical differences
were evaluated by two-tailed Student’s t-tests. For all analyses, we
considered p < 0.05 to be statistically significant.
Study approval
Collection of human skin biopsies was approved by the local (Cen-
tre Hospitalier Universitaire Vaudois) and cantonal (Canton de
Vaud) research ethics committees. All experiments involving
animals were approved by the Veterinary Office of the Canton Vaud
(Switzerland) in accordance with the Federal Swiss Veterinary
Office Guidelines. All experiments conform to European Commis-
sion Directive 86/609/EEC.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
The incidence of non-melanoma skin cancer (NMSC) is increasing at a
high rate, with over one million estimated new cases each year in the
United States alone. Squamous cell carcinoma (SCC) and basal cell carci-
noma, which both derive from keratinocytes, account for approximately
96% of all diagnosed skin cancers. Although mortality from NMSC is
low, morbidity is high and is accompanied by a heavy personal bur-
den and enormous rising costs for society. NMSCs are associated with
excessive and/or chronic exposure to ultraviolet (UV) radiation, espe-
cially UVB, and mainly occur on sun-exposed areas. Despite the preva-
lence of NMSCs, the molecular mechanisms underlying their
progression remain poorly defined. In skin, roles for the peroxisome
proliferator-activated receptor beta/delta (PPARb/d), a member of the
nuclear receptor superfamily, have been emphasized by its implication
in keratinocyte adhesion, migration and survival during tissue repair.
These processes also participate in skin cancer progression. However,
whether PPARb/d is pro- or anti-carcinogenic remains controversial
because both effects have been observed. We therefore investigated in
vivo whether PPARb/d might be involved in UV-induced skin carci-
noma, using SKH-1 hairless albino mice lacking PPARb/d activity, a
relevant model for studying human UV-induced skin cancer.
Results
In vivo and in cellulo, we characterized a cascade of events involving
PPARb/d as a regulator of oncogene Src transcription. We found that
UV induces PPARb/d activity, which in turn stimulates Src gene
expression, resulting in increased Src protein expression. We further
demonstrated that UV exposure activates Src and enhances the EGFR/
Erk1/2 signalling pathway, resulting in increased PPARb/d-dependent
pro-tumoural gene expression. In line with this, PPARb/d-null mice
developed fewer and less advanced tumours compared to wild-type
mice. Moreover, topical application of a PPARb/d antagonist prevented
UV-dependent stimulation of the Src/EGFR/Erk1/2 signalling pathway.
In human SCCs, PPARB/D expression was also positively correlated
with SRC expression. In a wide variety of human carcinomas from
various tissue origins, we identified an interaction among PPARB/
D, SRC and TGFB1 at the transcriptional level, which suggests a broad
pro-tumourigenic potential of PPARb/d via SRC upregulation.
Impact
Our present work motivates the future evaluation of PPARb/d antago-
nists as putative anti-cancer drugs that could be used to prevent skin
carcinoma progression and, potentially, epithelial cancers from other
tissue origin. Interestingly, Desatinib (Sprycel), a dual BCR/ABL and Src
family tyrosine kinase inhibitor previously used in patients with acute
myeloid leukaemia, is currently being assessed in a phase II clinical
trial for its ability to inhibit Src activity and treat SCC. The identifica-
tion of PPARb/d as a regulator of Src gene expression will further help
to refine this therapeutic strategy.
In addition, interest is increasing in PPARb/d agonists for treating
patients with metabolic syndrome through a stimulatory effect on
lipid oxidation in skeletal muscle. A PPARb/d agonist is currently being
tested in a phase IV clinical trial with obese patients showing dyslipi-
demia. Our data underscore the necessity of a careful evaluation of
the use of high-affinity PPARb/d agonists, especially in conditions
necessitating long-term treatment.
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